This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be
treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8
weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative
stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress -
related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.